Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]
News [6483]
Articles [133]
Editorials [5]
Conferences [171]
elearning [10]
Potential of PARP inhibitors for metastatic breast cancer
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
Targeting agent enfortumab vedotin a novel treatment for patients with advanced...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
New agent targeting Nectin-4 produces responses in nearly half of patients with...
Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )
3 Jun 2019
No difference in survival between laparoscopic surgery and open surgery in...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...
Dr Hedy Kindler - University of Chicago, Chicago, USA
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )
2 Jun 2019
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti...
Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany
AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )
1 Jun 2019
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
PARP inhibitors are a promising alternative to chemotherapy for patients with...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as...
Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019
Ovarian cancer: Current treatments and latest advances
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Ovarian cancer: Current treatments and latest advances ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019
Latest in ovarian cancer treatment
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019
Artificial intelligence and treatment decisions
Dr Pratik Shah - Massachusetts Institute of Technology, Cambridge, USA
Artificial intelligence and treatment decisions ( Dr Pratik Shah - Massachusetts Institute of Technology, Cambridge, USA )
24 May 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation